MilliporeSigma Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics
Adds to MilliporeSigma’s lipid manufacturing expertise, providing an integrated offering across mRNA value chain AmpTec’s differentiated polymerase chain reaction (PCR)-based technology has shown to have advantages over other technologies for mRNA manufacturing Diagnostics business focused on producing customized long RNAs and DNAs for in vitro diagnostics, complements existing MilliporeSigma portfolio Burlington, Massachusetts, January 7, 2020 — MilliporeSigma today... Read more